September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
Your daily dose of the clinical news you may have missed.
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
August 27th 2024
The Omnipod 5 is now the first automated insulin delivery system available for both T1D and T2D in the US.
August 16th 2024
Primary care clinicians can screen at-risk individuals for type 1 diabetes with a single autoantibody panel. It pays to test and educate early, according to this author.
Case 2: Prevention of Diabetic Retinopathy in a Patient with Type 2 Diabetes
Allen Dobson, Jr., MD, FAAFP, reviews the case of a 49-year-old woman with type 2 diabetes and the panel comments on their approaches to continued care and disease prevention.
Diabetic Retinopathy Screening Cost of Care and Practice Value
Wade Brosius, DO, and Steven Peskin, MD, review the cost of care and reimbursement schemes available to practitioners completing diabetic retinopathy screenings.
Recognizing and Addressing Barriers to Diabetic Retinopathy Screening
Key opinion leaders in diabetes management provide insight on recognizing and addressing barriers to care and screening for diabetic retinopathy.
Case 1: New Patient Screening and Initial Diagnosis of Diabetic Retinopathy
Allen Dobson, Jr., MD, FAAFP, reviews the case of a 67-year-old man with type 2 diabetes and the panel discusses initial diagnosis and management.
Diabetic Retinopathy Screening Guidelines and the Role of the Ophthalmologist
Key opinion leaders in diabetes management comment on the practical considerations of screening in clinical practices and note the importance of creating a replicable workflow for busy practices.
Practical Considerations in Diabetic Retinopathy Screening
An expert in the management of diabetes provides insight into common challenges leading to low rates of diabetic retinopathy screening in primary care settings, highlighting the need to increase access to care.
Clinical and Economic Burden of Diabetic Retinopathy
Wade Brosius, DO, and Steven Peskin, MD, discuss the clinical and economic burden of diabetic retinopathy, highlighting the impact on patients’ quality of life and the health care system.
Diabetic Retinopathy: Overview and Pathogenesis
Allen Dobson, Jr., MD, FAAFP; Wade Brosius, DO; and Shelton Hager, MD, provide an overview of diabetic retinopathy and discuss risk factors leading to its pathogenesis.
Utilizing CGMs for Diabetes Management in COVID-19
An expert in diabetes management discusses the role of CGMs in treating diabetes during the COVID-19 pandemic and the benefits of using CGM in telemedicine.
Patient Selection for CGMs in Diabetes
Dr Diana Isaacs provides insight on patient factors to consider for CGM use in diabetes treatment.
Role of Continuous Glucose Monitoring (CGM) in Diabetes Management
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, reviews the advantages of CGMs in treating type 1 and type 2 diabetes and how CGMs can improve glycemic control and quality of life in patients.
New Diabetes Device Comparison Platform Supports Clinical Decision-making, Prescribing
DiabetesWise Pro, created at Stanford University, provides an unbranded, unbiased guide to matching diabetes technology to patient needs, access, and lifestyle.
Empagliflozin CKD Phase 3 Trial Stopped Early for Positive Efficacy Seen in Interim Assessment
The phase 3 EMPA-KIDNEY clinical trial had just met prespecified criteria for positive efficacy when the study's Independent Data Monitoring Committee recommended the early halt.
CGM-measured Glucose Variability Associated with Diabetes Micro- and Macrovascular Complications
Glycemic variability and low time in range were associated with retinopathy, nephropathy, neuropathy, and CVD in a cohort of more than 20 000 persons, most with T2D.
In Patients with T2D and ASCVD, Prescriptions for Evidence-based Therapies Far from Adequate
US patients at high CV risk do not receive adequate evidence-based pharmacotherapy, according to large multisite cohort analysis.
NOACs Linked to Lower Risk for Vascular Issues than Warfarin in Patients with Diabetes, Atrial Fibrillation
Researchers in Taiwan found NOACs were associated with lower hazards of diabetes complications. and death than warfarin in persons with AF and DM.
Diabetes Care & Education Specialists, ADA Update National Standards for Diabetes Self-management Education and Support
The 2022 DSMES National Standards update focuses on reducing administrative burden on educators and improving person-centered care for patients.
FDA Approves Eversense E3 CGM System for Use up to 6 Months
The 180-day sensor life doubles the period of continuous use and cuts in half the number of CGM removals and reinsertions, without loss of accuracy.
Risk for Diabetes in Older Women Reduced by 12% with 2000 Steps per Day: Study
Higher daily step counts by women aged ≥65 years was associated with reduced risk for incident diabetes, an effect that was modified by the level of stepping intensity.
Blood Glucose Levels in T2D: 42 Factors that Make A Difference
These 42 factors that affect blood glucose are listed in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.
Tirzepatide Found Safe, Effective as Add-on to Stable Basal Insulin in T2D Patients Not at Goal
Tirzepatide at 3 different doses significantly improved glycemic control and promoted weight loss when added to titrated insulin in patients with type 2 diabetes.
Call for a NAFLD Care Pathway in T2D in Primary Care
Integrating NAFLD as a diabetes complication to be addressed during routine cycles of care could reduce barriers to a NAFLD pathway in primary care, agreed focus group participants.
Your T2D Patient Needs Mealtime Insulin: Counsel on Options, then Move Ahead
NYU endocrinologist Brian Levy, MD, offers perspective on keeping the transition from basal insulin to multiple daily injections as simple as possible for patient and provider.
Barriers to Intensifying Insulin in T2D Management: An Interview on Clinical Inertia
Type 2 diabetes patients-and their PCPs-may have trouble moving to basal + mealtime insulin from basal insulin alone. Endocrinologist Brian Levy, MD, offers insights.
Painful Diabetic Neuropathy Treatment: A Guideline Topline
The American Academy of Neurology recently issued a guideline on oral and topical treatments for painful diabetic neuropathy. Here, a concise summary for clinicians.
CGM-derived Time in Range Found Similar to A1c for Predicting Microvascular Complications in T2D
Use of continuous glucose monitoring to assess time in target glucose range in T2D patients was evaluated in a systematic literature review covering ~14 000 participants.
Obesity Expert Highlights 2021 Research Success, Looks to 2022 and Beyond
WATCH: The FDA approval of semaglutide 2.4 mg for adults with obesity was "by far the big event in 2021," said Donna Ryan, MD. More from our look back/look ahead interview, here.
American Diabetes Association Publishes Standards of Medical Care for 2022
The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.
Current Advances in Continuous Glucose Monitoring Technology
CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent enhancements.
Continuous Glucose Monitoring for Type 2 Diabetes in Primary Care: 2021 Research Review
Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.